Despite the success of targeted therapies in cancer treatment, therapy-induced resistance
remains a major obstacle to a complete cure. Tumor cells evade treatments and relapse via …

Experimental evidence accumulated over decades has implicated epithelial–mesenchymal
plasticity (EMP), which collectively encompasses epithelial–mesenchymal transition and the …

Resistance to cancer therapy is a major barrier to cancer management. Conventional views
have proposed that acquisition of resistance may result from genetic mutations. However …

Immune checkpoint blockage has been considered a breakthrough in cancer treatment,
achieving encouraging anti-tumor effects in some advanced solid malignancies. However …

Therapy resistance is a characteristic of cancer cells that significantly reduces the
effectiveness of drugs. Despite the popularity of cisplatin (CP) as a chemotherapeutic agent …

Novel immunotherapy approaches have provided durable remission in a significant number
of cancer patients with cancers previously considered rapidly lethal. Nonetheless, the high …

Although the role of PD-L1 in suppressing the anti-tumor immune response is extensively
documented, recent discoveries indicate a distinct tumor-intrinsic role for PD-L1 in …

Chemoresistance remains a major complication of cancer treatments. Recent data provide
strong evidence that chemoresistance is linked to epithelial–mesenchymal transition (EMT) …

Background PD-L1 enhanced the tumorigenesis and immune escape abilities of cancers.
The upstream mechanisms of PD-L1 in regulating tumorigenesis and immune escape of …

Background The cisplatin-resistance is still a main course for chemotherapy failure of lung
cancer patients. Cisplatin-resistant cancer cells own higher malignance and exhibited …